keyword
MENU ▼
Read by QxMD icon Read
search

Vaginal atrophy

keyword
https://www.readbyqxmd.com/read/27904630/a-survey-of-the-therapeutic-effects-of-vitamin-e-suppositories-on-vaginal-atrophy-in-postmenopausal-women
#1
Aazam Parnan Emamverdikhan, Nahid Golmakani, Sayyed ASajadi Tabassi, Malihe Hassanzadeh, Nooriyeh Sharifi, Mohammad Taghi Shakeri
BACKGROUND: Menopause is associated with various complications such as depression, sleep disorders, and genitourinary atrophy. Vaginal atrophy occurs due to the loss of steroid hormones, and its major symptoms include vaginal dryness, itching, dyspareunia, and bleeding after intercourse. According to the literature, vitamin E plays a key role in estrogen stability. The aim of this study was to compare the effects of vitamin E suppositories and conjugated estrogen vaginal cream on vaginal atrophy...
September 2016: Iranian Journal of Nursing and Midwifery Research
https://www.readbyqxmd.com/read/27896230/evaluation-of-symptoms-and-prevention-of-cancer-in-menopause-the-value-of-vulvar-exam
#2
A R Palumbo, C Fasolino, G Santoro, V Gargano, M Rinaldi, B Arduino, M Belli, M Guida
Vulvar and vaginal atrophy (VVA), is a chronic medical condition experienced by postmenopausal women, with prevalence estimated ranging from 10% to 50% [1]. VVA is characterized by a constellation of symptoms, that may affect daily activities, sexuality, relationships, and quality of life [3]. Early recognition and effective treatment of VVA may enhance sexual health and the quality of life of women and their partners. Some vulvar conditions such as lichen sclerosus are more prevalent in the postmenopausal years...
November 2016: Translational Medicine @ UniSa
https://www.readbyqxmd.com/read/27875388/is-vulvovaginal-atrophy-due-to-a-lack-of-both-estrogens-and-androgens
#3
Fernand Labrie, Céline Martel, Georges Pelletier
OBJECTIVE: The aim of this study was to review the preclinical data showing the role of both estrogens and androgens in the physiology of the vagina, and, most likely, in vulvovaginal atrophy of menopause. METHODS: Mass spectrometry-based assays (validated according to the FDA guidelines) for the measurement of sex steroids, their precursors, and metabolites were used. In addition to fixation of the vagina for morphological examination, histomorphometry, immunocytochemistry, immunofluorescence, and quantitative reverse transcription polymerase chain reaction were performed...
November 21, 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27832260/vaginal-testosterone-cream-vs-estradiol-vaginal-ring-for-vaginal-dryness-or-decreased-libido-in-women-receiving-aromatase-inhibitors-for-early-stage-breast-cancer-a-randomized-clinical-trial
#4
Michelle E Melisko, Mindy E Goldman, Jimmy Hwang, Amy De Luca, Sally Fang, Laura J Esserman, Amy J Chien, John W Park, Hope S Rugo
Importance: Aromatase inhibitors (AI) are associated with significant urogenital atrophy, affecting quality of life and drug compliance. Objective: To evaluate safety of intravaginal testosterone cream (IVT) or an estradiol-releasing vaginal ring (7.5 μg/d) in patients with early-stage breast cancer (BC) receiving an AI. Intervention was considered unsafe if more than 25% of patients had persistent elevation in estradiol (E2), defined as E2 greater than 10 pg/mL (to convert to pmol/L, multiply by 3...
November 10, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27831658/postmenopausal-vulvovaginal-atrophy-vva-is-positively-improved-by-topical-hyaluronic-acid-application-a-prospective-observational-study
#5
M Origoni, C Cimmino, G Carminati, E Iachini, C Stefani, S Girardelli, S Salvatore, M Candiani
OBJECTIVE: To evaluate the effectiveness of a topical vaginal preparation containing hyaluronic acid in controlling signs and symptoms correlated with postmenopausal vulvovaginal atrophy (VVA). PATIENTS AND METHODS: A prospective, observational study has been performed at the Obstetrics and Gynecology Department of the Vita Salute San Raffaele University of Milan, Italy. Forty-six (46) consecutive postmenopausal women complaining of genital discomfort due to postmenopausal estrogen lack have been enrolled...
October 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27830882/histological-changes-in-the-vulva-and-vagina-from-ovariectomised-rats-undergoing-oestrogen-treatment
#6
Radu Florin Mocan-Hognogi, Nicolae Costin, Andrei Malutan, Razvan Ciortea, Ioana Alexandra Trif, Andras Laszlo Nagy, Marian Liviu Bogdan, Dan Mihu
BACKGROUND: The purpose of this study was to assess the histological changes occurring in the vagina and vulva in ovariectomised female rats, as well as the response to the administration of injectable oestrogens. MATERIAL AND METHODS: We used 30 female Wistar white rats, distributed as follows: group 1 - the control group, group 2 - the operated but untreated rats, and groups 3, 4 and 5, operated rats, to which oestrogenic treatment was administered (Estradiol, Estradurin, Sintofolin), at a dosage of 0...
November 10, 2016: Folia Morphologica (Warsz)
https://www.readbyqxmd.com/read/27822125/clinical-update-on-the-use-of-ospemifene-in-the-treatment-of-severe-symptomatic-vulvar-and-vaginal-atrophy
#7
REVIEW
Santiago Palacios, María Jesús Cancelo
The physiological decrease in vaginal estrogens is accountable for the emergence of vulvar and vaginal atrophy (VVA) and its related symptoms such as vaginal dryness, dyspareunia, vaginal and/or vulvar irritation or itching, and dysuria. The repercussion of these symptoms on quality of life often makes it necessary to initiate treatment. Up until now, the treatments available included vaginal moisturizers and lubricants, local estrogens, and hormonal therapy. However, therapeutic options have now been increased with the approval of 60 mg ospemifene, the first nonhormonal oral treatment with an agonist effect on the vaginal epithelium and an endometrial and breast safety profile which makes it unique...
2016: International Journal of Women's Health
https://www.readbyqxmd.com/read/27817837/estrogen-progestins-and-progestins-for-the-management-of-endometriosis
#8
REVIEW
Paolo Vercellini, Laura Buggio, Nicola Berlanda, Giussy Barbara, Edgardo Somigliana, Silvano Bosari
Endometriosis is characterized by frequent recurrences of symptoms and lesions even after extirpative surgery. Because medical therapies control but do not cure the disease, long periods of pharmacologic management may be needed until pregnancy desire or, sometimes, physiologic menopause. Hormonal drugs suppress ovulation and menstruation and have similar beneficial effects against pain. However, only estrogen-progestins and progestins have safety/tolerability/cost profiles that allow long-term use. These compounds induce atrophy of eutopic and ectopic endometrium, have antiinflammatory and proapoptotic properties, and can be delivered via different modalities, including oral, transdermal, subcutaneous, intramuscular, vaginal, and intrauterine routes...
November 4, 2016: Fertility and Sterility
https://www.readbyqxmd.com/read/27749740/comparison-of-pueraria-mirifica-gel-and-conjugated-equine-estrogen-cream-effects-on-vaginal-health-in-postmenopausal-women
#9
Narathorn Suwanvesh, Jittima Manonai, Areepan Sophonsritsuk, Wichai Cherdshewasart
OBJECTIVES: To compare the effects of a 12-week treatment with Pueraria mirifica (PM) gel or a conjugated estrogen cream on vaginal maturation index, vaginal symptom score, vaginal health assessment score, and vaginal flora in postmenopausal women. METHODS: In a prospective, noninferiority, randomized controlled study, 82 postmenopausal women with at least one vulvovaginal symptom, that is, dryness, soreness, irritation, dyspareunia, or discharge, were recruited...
October 3, 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27736240/medical-and-patient-attitude-towards-vaginal-atrophy-the-agata-study
#10
F Palma, E Della Vecchia, A Cagnacci
OBJECTIVES: To provide data on current management of vaginal atrophy (VA) in a nationwide setting. METHODS: A cross-sectional, multicenter study was made in 913 postmenopausal women consulting 22 gynecological outpatient services. VA was diagnosed with a combination of subjective symptoms and objective evaluations. Women with a previous diagnosis and those with a new diagnosis of VA filled additional questionnaires regarding modalities of VA management and reasons for missing diagnosis, respectively...
October 13, 2016: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/27735020/ospemifene-a-safe-treatment-of-vaginal-atrophy
#11
L Del Pup
OBJECTIVE: Vaginal atrophy is a chronic, progressive medical condition that affects fifty percent of postmenopausal women, causing symptoms like dyspareunia, vaginal dryness, and vaginal irritation. Until recently, the only prescription options were systemic and vaginal estrogen therapies that might be limited by concerns about long-term safety and breast cancer risk. The objective is to analyze the literature about ospemifene, a tissue-selective estrogen receptor modulator (SERM) recently approved for the treatment of vulvovaginal atrophy and dyspareunia and to compare its effects with those of the other SERMs to assess its safety...
September 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27692842/tx-004hr-improves-sexual-function-as-measured-by-the-female-sexual-function-index-in-postmenopausal-women-with-vulvar-and-vaginal-atrophy-the-rejoice-trial
#12
Sheryl A Kingsberg, Leonard Derogatis, James A Simon, Ginger D Constantine, Shelli Graham, Brian Bernick, Gina Gasper, Sebastian Mirkin
INTRODUCTION: TX-004HR is an investigational, applicator-free, vaginal soft gel capsule containing low-dose solubilized 17β-estradiol. The phase 3, randomized, double-blinded, placebo-controlled, multicenter REJOICE trial has shown TX-004HR to be safe and effective for the treatment of moderate to severe dyspareunia in postmenopausal women with vulvar and vaginal atrophy (VVA). AIM: To evaluate the effect of TX-004HR on female sexual dysfunction in postmenopausal women with VVA...
September 27, 2016: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/27642295/differential-regulation-of-morphology-and-estrogen-receptor-alpha-expression-in-the-vagina-of-ovariectomized-adult-virgin-rats-by-estrogen-replacement-a-histological-study
#13
Ting Li, Yuanyuan Ma, Hong Zhang, Ping Yan, Lili Huo, Yongyan Hu, Xi Chen, Ting Li, Miao Zhang, Zhaohui Liu
Background. To determine the exact role of estrogen in vaginal tissue morphology and estrogen receptor-alpha (ERα) distribution in the vagina, which remains controversial. Methods. Sixty rats were randomly categorized: sham-operated (sham), ovariectomy (OVX), and four estradiol treatments (estradiol valerate at 0.4, 0.8, 1.6, and 3.2 mg/kg/day) for 2 weeks. Thereafter, vaginal samples were biopsied from the distal- and proximal-half portions. The percentage of ERα-immunoreactive cells and the ERα score were quantified using immunohistochemistry to assess changes in ERα expression and distribution...
2016: International Journal of Endocrinology
https://www.readbyqxmd.com/read/27638008/influence-of-contraceptive-choice-on-vaginal-bacterial-and-fungal-microflora
#14
G Donders, G Bellen, D Janssens, B Van Bulck, P Hinoul, J Verguts
The influence of contraception on vaginal microflora can have a major impact on the risk of developing acute or recurrent vaginal infections, but also may influence the risk of acquiring sexually transmissible infections (STI) such as HIV. A cohort of 248 women presenting for levonorgestrel-releasing intrauterine system (LNG-IUS) insertion or reinsertion were stratified according to their current contraceptive method. Information concerning their menstrual pattern and data about the medical history were collected...
September 9, 2016: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/27636306/menopausal-hormone-therapy-age-and-chronic-diseases-perspectives-on-statistical-trends
#15
Judy L Bolton
The release of the Women's Health Initiative (WHI) study in 2002 was a shock to the medical community. Hormone therapy (HT) had generally been considered to be highly beneficial for postmenopausal women since it was the gold standard for relief of menopausal symptoms (hot flashes, night sweats, vaginal atrophy) and it was thought to protect women from osteoporosis, heart disease, and cognitive decline and to generally improve quality of life. However, WHI showed a statistically significant increase in a number of disease states, including breast cancer, cardiovascular disease, and stroke...
October 17, 2016: Chemical Research in Toxicology
https://www.readbyqxmd.com/read/27636220/risk-factors-for-microscopic-hematuria-in-women
#16
Lee A Richter, Quinn K Lippmann, Karl Jallad, Joelle Lucas, Jennifer Yeung, Tanaka Dune, Erin Mellano, Steven Weissbart, Mihriye Mete, Ja-Hong Kim, Robert Gutman
OBJECTIVES: The objective of this study was to determine the risk factors that may contribute to the diagnosis of microscopic hematuria (MH) in women. METHODS: This multicenter case-control study reviewed cases of women presenting to Female Pelvic Medicine & Reconstructive Surgery sites with MH from 2010 to 2014. Microscopic hematuria was defined as 3 or more red blood cells per high power field in the absence of infection as indicated in the American Urologic Association guidelines...
September 16, 2016: Female Pelvic Medicine & Reconstructive Surgery
https://www.readbyqxmd.com/read/27608749/transcutaneous-temperature-controlled-radiofrequency-ttcrf-for-the-treatment-of-menopausal-vaginal-genitourinary-symptoms
#17
Gustavo Leibaschoff, Pablo Gonzalez Izasa, Jose Luis Cardona, John R Miklos, Robert D Moore
OBJECTIVE: The aim of this study was to evaluate the effects of non-ablative, monopolar transcutaneous temperature controlled radiofrequency (TTCRF) technology in the treatment of postmenopausal women suffering from genuine stress urinary incontinence (SUI) related to menopause and to evaluate histological changes vaginally associated with the treatment. MATERIALS AND METHODS: Subjective and objective symptoms of SUI were assessed in study subjects before and after TTCRF, (1 treatment every 30 days, for 3 months; n=10) and compared with the effects of a placebo treatment on a control group of demographically similar women (n =10)...
September 10, 2016: Surgical Technology International
https://www.readbyqxmd.com/read/27603220/putative-functions-of-tissue-kallikrein-related-peptidases-in-vaginal-fluid
#18
REVIEW
Carla M J Muytjens, Stella K Vasiliou, Katerina Oikonomopoulou, Ioannis Prassas, Eleftherios P Diamandis
Cervical-vaginal fluid (CVF) is a complex biological fluid that hydrates the mucosa of the lower female reproductive system. In-depth proteomic and biochemical studies on CVF have revealed that it contains large amounts of endogenous proteases and protease inhibitors, including an abundance of several members of the tissue kallikrein-related peptidase (KLK) family. Despite their ubiquitous presence in human tissues and fluids, KLK expression levels vary considerably, with maximum expression observed in reproduction-related tissues and fluids...
October 2016: Nature Reviews. Urology
https://www.readbyqxmd.com/read/27577677/local-oestrogen-for-vaginal-atrophy-in-postmenopausal-women
#19
REVIEW
Anne Lethaby, Reuben Olugbenga Ayeleke, Helen Roberts
BACKGROUND: Vaginal atrophy is a frequent complaint of postmenopausal women; symptoms include vaginal dryness, itching, discomfort and painful intercourse. Systemic treatment for these symptoms in the form of oral hormone replacement therapy is not always necessary. An alternative choice is oestrogenic preparations administered vaginally (in the form of creams, pessaries, tablets and the oestradiol-releasing ring). This is an update of a Chochrane systematic review; the original version was first published in October 2006...
August 31, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27517339/what-s-new-in-the-world-of-postmenopausal-sex
#20
Cheryl B Iglesia
PURPOSE OF REVIEW: The purpose of this review is to describe new terminology for vulvovaginal atrophy and female sexual dysfunction and to highlight recent findings related to vaginal moisturizers, lubricants and prescription estrogen preparations. RECENT FINDINGS: Sexual health is a marker for overall health. A minority (40%) of healthcare providers routinely ask about sexual problems and its impact on quality of life. New terminology by the American Psychiatric Association divides female sexual disorders into three categories: arousal/interest disorder, orgasmic disorder and genital pain and penetration disorder...
October 2016: Current Opinion in Obstetrics & Gynecology
keyword
keyword
19676
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"